Want to see TEM full AI Analyst Report?
TEM Stock Chart & Stats
$68.73
-$3.32(-7.22%)
At close: 4:00 PM EDT
$68.73
-$3.32(-7.22%)
Day’s Range― - ―
52-Week Range$40.77 - $104.32
Previous CloseN/A
Volume5.79M
Average Volume (3M)7.97M
Market Cap
$15.34B
Enterprise Value$11.19K
Total Cash (Recent Filing)$815.99M
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)―
Beta2.90
Next Earnings
Nov 10, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding175,390,960
10 Day Avg. Volume8,299,706
30 Day Avg. Volume7,965,441
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)20.94
Price to Sales (P/S)8.09
P/FCF Ratio-41.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$67.88Price Target Upside-1.23% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$1.60B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Scale And Gross MarginRapid revenue expansion combined with gross margin near 70% indicates strong demand and attractive underlying economics in Tempus’s diagnostics and data businesses. If maintained, this gross profit base can support continued investment in technology, clinical capabilities, and commercial expansion.
Diagnostics And Data Licensing GrowthGrowth across both oncology diagnostics and data licensing demonstrates that Tempus is scaling more than one revenue stream. Broad-based adoption can improve operating leverage over time and deepen the value of the company’s clinical, molecular, and commercial data platform.
Expanding Precision-oncology PlatformFDA-cleared diagnostic capabilities, foundation-model deployment, and the proposed addition of MRD technology broaden Tempus’s precision-oncology offering. A wider product platform may strengthen provider and biopharma relationships while increasing opportunities to reuse data across care and research.
Bears Say
Persistent Operating And Net LossesDespite strong top-line growth and high gross margins, Tempus remains materially unprofitable below the gross-profit line. Continued operating losses could delay self-funded expansion and make the company’s ability to convert scale into durable earnings a key execution challenge.
High Leverage Limits FlexibilityDebt materially exceeds equity, leaving Tempus with less financial flexibility while it continues investing and reporting losses. This capital structure can constrain future choices, increase dependence on financing capacity, and reduce resilience if operating performance takes longer to improve.
Ongoing Cash ConsumptionNegative operating and free cash flow show that the business is not yet funding itself internally. Persistent cash consumption increases reliance on external capital while Tempus pursues profitability, potentially limiting investment flexibility and raising the importance of disciplined cash management.
Tempus AI, Inc. Class A News
TEM FAQ
What was Tempus AI, Inc. Class A’s price range in the past 12 months?
Tempus AI, Inc. Class A lowest stock price was $40.77 and its highest was $104.32 in the past 12 months.
What is Tempus AI, Inc. Class A’s market cap?
Tempus AI, Inc. Class A’s market cap is $15.34B.
When is Tempus AI, Inc. Class A’s upcoming earnings report date?
Tempus AI, Inc. Class A’s upcoming earnings report date is Nov 10, 2026 which is in 42 days.
How were Tempus AI, Inc. Class A’s earnings last quarter?
Tempus AI, Inc. Class A released its earnings results on Jul 30, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.103.
Is Tempus AI, Inc. Class A overvalued?
According to Wall Street analysts Tempus AI, Inc. Class A’s price is currently Overvalued.
Does Tempus AI, Inc. Class A pay dividends?
Tempus AI, Inc. Class A does not currently pay dividends.
What is Tempus AI, Inc. Class A’s EPS estimate?
Tempus AI, Inc. Class A’s EPS estimate is -0.08.
How many shares outstanding does Tempus AI, Inc. Class A have?
Tempus AI, Inc. Class A has 175,390,960 shares outstanding.
What happened to Tempus AI, Inc. Class A’s price movement after its last earnings report?
Tempus AI, Inc. Class A reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went down -0.948%.
Which hedge fund is a major shareholder of Tempus AI, Inc. Class A?
Currently, no hedge funds are holding shares in TEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tempus AI, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.88 (-1.23% Downside)
$67.88 (-1.23% Downside)
Blogger Sentiment
Bullish
TEM Sentiment 84%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 513.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
45.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tempus AI, Inc. Class A
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Company Deck
TEM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong topline momentum and durable demand in both diagnostics and data/applications: revenue growth (~36% YoY), robust Data & Insights growth (40.5% YoY; Insights >44%), expansion of large pharma collaborations (Merck, Gilead), rising bookings/TCV and an upgraded full-year revenue guide to $1.59B–$1.60B with adjusted EBITDA targeted at ~$65M. Key risks and near-term headwinds include Q1 cash-flow timing effects, slower hereditary volumes early in the year, MRD reimbursement and scaling constraints, and some regulatory timing uncertainty. Overall the positives (strong growth, expanding high-value contracts, improving EBITDA trajectory and sizable data assets) outweigh the transitory operational and reimbursement challenges.View all TEM earnings summariesTEM Stock 12 Month Forecast
Average Price Target
$67.88
▼(-1.23% Downside)
Technical Analysis
Ownership Overview
21.58% Insiders
8.84% Mutual Funds
26.79% Other Institutional Investors
26.69% Public Companies and Individual Investors